For Healthcare Professionals

Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients

clipboard-pencil

About the study

ECMO has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. However bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. The aim is to investigate the occurence of bleeding and its frequency according to the type of ECMO either veno-arterial or veno-venous. The investigators also want to assess the relation of bleeding with von Willebrand Factor defects.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. informed consent of patient or person in charge
  2. patient supplied by an ECMO for cardiac or respiratory failure and referred to Lille University Hospital
  3. patient affiliated to "french social security"

EXCLUSION CRITERIA

Exclusion Criteria:

  1. pregnant woman
  2. no consent
  3. no affiliation to
  4. patient affiliated to '
  5. preexisting bleeding disorders
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 320445962 (poste 29673)Email iconEmail Study Center

Study Details


Contition

Von Willebrand Diseases

Age

18+

Participants Needed

418

Est. Completion Date

May 31, 2026

Treatment Type

OBSERVATIONAL


Sponsor

University Hospital, Lille

ClinicalTrials.gov NCT Identifier

NCT03070912

Study Number

201583

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.